A recent study has shown poorer clinical outcomes for breast cancer patients diagnosed with invasive, early-onset breast cancer who carry a CHEK2 pathogenic variant (Greville-Heygate et al., 2020). This evidence concerns the gene CHEK2 and breast cancer.